ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part D

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoarthritis

Conditions

Osteoarthritis

Trial Timeline

May 1, 2015 โ†’ Apr 1, 2016

About ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part D

ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part D is a phase 1 stage product being developed by Ono Pharmaceutical for Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02454387. Target conditions include Osteoarthritis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02454387Phase 1Completed

Competing Products

20 competing products in Osteoarthritis

See all competitors
ProductCompanyStageHype Score
Duloxetine + PlaceboEli LillyPhase 3
77
LY2828360 + PlaceboEli LillyPhase 2
52
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
77
Duloxetine + Sugar pillEli LillyApproved
85
UBX0101 or placeboUnity BiotechnologyPre-clinical
15
UBX0101Unity BiotechnologyPhase 1
25
UBX0101Unity BiotechnologyPhase 2
44
UBX0101Unity BiotechnologyPhase 1
25
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
52
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
77
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
52
Capsaicin Topical SolutionAstellas PharmaApproved
85
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
52
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
52
Duloxetine + PlaceboShionogiPhase 3
77
DuloxetineShionogiPhase 3
77
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
52
Duloxetine + PlaceboEli LillyPhase 3
77
LY3556050 + PlaceboEli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77